About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Long-Term Study of MP-214 in Patients With Schizophrenia

Long-Term Study of MP-214 in Patients With Schizophrenia

NCT01626872·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Tanabe Pharma Corporation

Age

20–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Written informed consent obtained from the patient before the completion of Study A002-A4
Patients who have completed the A002-A4 study

You may not be if

Patients who are experiencing ongoing, uncontrolled, clinically significant adverse events (AEs), as judged by the investigator (or subinvestigator)
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

The record

StatusCompleted

PhasePhase 2–3

Taking part254

StartedSep 2012

UpdatedJan 5, 2026

Conditions

Where3

Sapporo, Hokkaido, Japan
Seoul, South Korea
Taipei, Taiwan